Anti CD38, SLAMF-7 and BiTE immunotherapy: Are immune therapeutics ready for the frontline?

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?Подробнее

Antibodies in Practice: SLAMF-7, CD38, Bispecific?Подробнее

MM: Are anti-BCMA immunotherapies ready for the frontline?Подробнее

Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myelomaПодробнее

SLAMF7 as a target for multiple myelomaПодробнее

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myelomaПодробнее

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEsПодробнее

CD38: a promising target for multiple myeloma antibody therapyПодробнее

Current research on anti-CD38 CAR T-cell therapiesПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

SLAMF7 Activating Natural Killer Cells for Potent Anti-Cancer ResponsesПодробнее

Dr. Berenson on Arming an Anti-CD38 Antibody With Interferon in MyelomaПодробнее

What immunotherapies are used in myeloma? Can IMiDs be considered a form of immunotherapy? #myelomaПодробнее

CD38 and SLAMF7 targeting for multiple myelomaПодробнее

Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myelomaПодробнее

Available CD38 Antibodies for Multiple MyelomaПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

New era for monoclonal antibody-based immunotherapy for treating multiple myelomaПодробнее

CD38 Antibodies in Multiple Myeloma: What Next?Подробнее